Your shopping cart is currently empty

M2698 (MSC2363318A) is an inhibitor of p70S6K, Akt1 and Akt3 with IC50s of 1 nM. M2698 shows anti-cancer activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $43 | In Stock | In Stock | |
| 5 mg | $107 | In Stock | In Stock | |
| 10 mg | $173 | In Stock | In Stock | |
| 25 mg | $347 | In Stock | In Stock | |
| 50 mg | $500 | In Stock | In Stock | |
| 100 mg | $690 | - | In Stock | |
| 200 mg | $929 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $125 | In Stock | In Stock |
| Description | M2698 (MSC2363318A) is an inhibitor of p70S6K, Akt1 and Akt3 with IC50s of 1 nM. M2698 shows anti-cancer activity. |
| Targets&IC50 | Akt3:1 nM, Akt1:1 nM, p70 S6K:1 nM |
| In vitro | M2698 (0.3 nM-50 M) dose-dependently inhibits proliferation in breast tumor cell lines (IC50s: 0.02-8.5 µM). M2698 (0.3-1 µM) induces feedback loop phosphorylation on Akt and suppresses Akt and p70S6K activity in HCC1419 and MDA-MB-453 cells. M2698 inhibits indirectly pGSK3β and pS6 with IC50s of 17 and 15 nM[1]. |
| In vivo | Gavage administration of M2698 (10-30 mg/kg) dose-dependently inhibits the growth of tumors and increases pAkt levels in tumor tissue. M2698 (30 mg/kg) causes tumor regression. M2698 (1-20 mg/kg) inhibits S6 phosphorylation in a dose-proportional manner over time[1]. |
| Synonyms | MSC2363318A |
| Molecular Weight | 449.86 |
| Formula | C21H19ClF3N5O |
| Cas No. | 1379545-95-5 |
| Smiles | N([C@H](CN1CCC1)C2=CC(C(F)(F)F)=C(Cl)C=C2)C=3C4=C(C(C(N)=O)=CC=C4)N=CN3 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 112.5 mg/mL (250.08 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.89 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.